Skip to content
Screener

Syndax Pharmaceuticals SNDX Q3 2025 earnings

Reported November 3, 2025 · After market close

Revenue$45.9MMiss by $17.5M
EPS-$0.70Beat by $0.04
Revenue estimate$63.3M
EPS estimate-$0.74

Next report

Nov 2, 2026 (in a month)
Revenue estimate$82.8M
EPS estimate-$0.51

Financials

Q3 2025

Income statement

See full
Revenue$45.9M+267%
Operating income-$57.4M+35.9%
Net income-$60.7M+27.8%
EPS (diluted)-$0.70+28.6%

Balance sheet

See full
Cash & equivalents$116.8M-12.2%
Total debt$327.4M+38,784%
Total equity$115.4M-68.5%
Total assets$551.8M+29.6%

Cash flow

See full
Operating cash flow-$70.5M-13.2%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.33B-19.3%
Enterprise value$1.54B+1.8%
P/S11.9×-90.7×

Profitability

See full
Operating margin-275.1%-127pp
Net margin-279.3%-128pp
FCF margin-278.9%-126pp

Returns & leverage

See full
Return on equity-129.3%+178pp
Debt / equity2.8×+2.8×
Current ratio4.6×-2.3×

FAQ

When did Syndax Pharmaceuticals report Q3 2025 earnings?
Syndax Pharmaceuticals (SNDX) reported Q3 2025 earnings on November 3, 2025 after market close.
What were Syndax Pharmaceuticals's Q3 2025 revenue and EPS?
Syndax Pharmaceuticals reported revenue of $45.9M and eps of $-0.70 for Q3 2025.
Did Syndax Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $63.3M by $17.5M. EPS beat the consensus estimate of $-0.74 by $0.04.
How did Syndax Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 267.0% from $12.5M a year earlier and eps grew 28.6% from $-0.98.
Where can I find Syndax Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-262509) and the 10-Q periodic report (0001193125-25-262521) directly on SEC EDGAR. The filing index links above go to sec.gov.